Seaport Therapeutics Inc.
- Address
- 101 Seaport Boulevard Floor 12
Sponsor Overview
Specializations
Major Depressive Disorder
Seaport Therapeutics Inc. focuses its clinical research on major depressive disorder, including presentations with anxious distress, in adult populations. The sponsor’s trial portfolio is centered on symptom reduction, psychiatric symptom control, and the clinical profile of investigational monotherapy approaches.
- Depressive symptom management
- Anxious distress in depression
- Adult psychiatry
Its research activity is concentrated in mood disorders and the evaluation of treatments intended for patients living with persistent depressive symptoms.
Psychiatric Therapeutics
The sponsor’s clinical development work is directed toward psychiatric therapeutics, with particular interest in oral treatment options for depressive illness. The research landscape includes assessment of safety, tolerability, and clinical effects relevant to everyday psychiatric care.
- Oral therapy
- Safety and tolerability
- Monotherapy in depression
These studies reflect a therapeutic emphasis on treatment options for central nervous system disorders within outpatient mental health settings.
Clinical Trial Operations
Based in Boston, United States, Seaport Therapeutics Inc. supports a multicountry research program with collaborating sites across North America and other active regions. Its trial activity spans multiple research centers, indicating engagement with broad clinical access in psychiatric study populations.
- Multicenter clinical research
- International trial network
- Recruiting studies
The sponsor’s operational footprint includes coordination across multiple countries and a network of collaborating research sites supporting ongoing psychiatric trials.
Depression Treatment Evaluation
Seaport Therapeutics Inc. is actively involved in the evaluation of investigational treatment approaches for depressive disorders, with attention to both clinical response and treatment acceptability. Its research focus remains centered on outcomes relevant to major depressive disorder care.
- Clinical response in MDD
- Treatment acceptability
- Psychiatric symptom improvement
The sponsor’s work is specifically aligned with advancing therapeutic options for adults affected by depression and associated anxious features.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Safety, and Tolerability of Brexanolone Caprilcerbate in Adults with Major Depressive Disorder with or without Anxious Distress: A Randomized, Double-Blind Study |  Bulgaria Czechia Germany Hungary Poland Romania Slovakia | Recruiting |
| Evaluation of Brexanolone Caprilcerbate Monotherapy in Adults with Major Depressive Disorder with or without Anxious Distress: A 6-Week Open-Label Study | Bulgaria Czechia Germany Hungary Poland Romania Slovakia | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 38 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders2 trials150 other sponsors
Partnered Research Centres
38 centres- Address
- Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
- Address
- Ligi Polskiej 5, 87-100 Torun
- Address
- Kaszasdulo Utca 5, 1033 Budapest
- Address
- Počernická 1427/16, 100 00 Prague
- Address
- M R Stefanika 2427, 093 01 Vranov nad Topľou
- Address
- Ul. Aldony 2a/3, 80-438 Gdansk
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Seaport Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.